Natural human antibodies retrieved by phage display libraries from healthy donors: Polyreactivity and recognition of human immunodeficiency virus type 1 gp120 epitopes

Scandinavian Journal of Immunology

Volumn 50, Issue 3, 1999, Pages 270-279

  Llorente, Mercedes ^a   Sanchez Palomino S ^b   Manes S ^a   Lucas, P ^a   Kremer, L ^a   De Alboran I M ^c   Toran J L ^a   Alcami J ^b   Del Real, G ^a   Martinez A C ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Centro de Investigación Experimentación y Servicios del champiñón CIES   (Spain)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; BACTERIOPHAGES; BASE SEQUENCE; BLOOD DONORS; CROSS REACTIONS; EPITOPES, B-LYMPHOCYTE; GENES, IMMUNOGLOBULIN; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY;

EID: 0032774675     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1999.00516.x     Document Type: Article

References (31)

1. 1 Haynes BF, Pantaleo G, Fauci A. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-8.
2. 2 Cerundolo V, Lahaye T, Horvath C, Zanovello P, Collavo D, Engers HD. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone. Eur J Immunol 1987;17:173-8.
3. 3 Earl PL, Moss B, Morrison RP, Wehrly K, Nishio J, Chesebro B. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science 1986;234:728-31.
4. 4 Kast WM, Roux L, Curren J, Blom HJ, Voordouw AC, Meloen RH, Kolakofsky D, Melief CJ. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA 1991;88:2283-7.
5. 5 Lukacher AE, Braciale VL, Braciale TJ. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 1984;160:814-26.
6. 6 Berberian L, Valles-Ayoub Y, Sun N, Martínez-Maza O, Braun J. A VH clonal deficit in human immunodeficiency virus-positive individuals reflects a B-cell maturational arrest. Blood 1991;78: 175-9.
7. 7 David D, Demaison C, Bani L, Zouali M, Thèze J. Selective variations in vivo of VH3 and VH1 gene family expression in peripheral B cell IgM, IgD and IgG during HIV infection. Eur J Immunol 1995;25:1524-8.
8. 8 Rodman TC, Laurence J, Pruslin FH, Chiorazzi N, Winston R. Naturally occurring antibodies reactive with sperm proteins: apparent deficiency in AIDS sera. Science 1985;228:1211-5.
9. 9 Rodman TC, To SE, Hashish H, Manchester K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci USA 1993;90:7719-23.
10. 10 Cook GP, Tomlinson IM. The human immunoglobulin VH repertoire. Immunol Today 1995;16:237-42.
11. 11 Guigou V, Cuisinier A-M, Tonelle C, Moinier D, Fougereau M, Fumoux F. Human immunoglobulin Vh and Vk repertoire revealed by in situ hybridization. Mol Immunol 1990;27:935-40.
12. 12 Cohen J. Jitters jeopardize AIDS vaccine trials. Science 1993;262: 980-1.
13. 13 Cohen J. The HIV vaccine paradox. Science 1994;264:1072-4.
14. 14 Paul WR. Can the immune response control HIV infection? Cell 1995;82:177-82.
15. 15 Parren PWHI, Burton DR. HIV-1 antibody-debris or virion? Nature Med 1997;3:366-7.
16. 16 Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, Roost H-P, Aguet M, Hengartner H, Zinkernagel RM. The role of antibody concentration and avidity in antiviral protection. Science 1997;276: 2024-7.
17. 17 Prince AM, Reesink H, Pascual D, Horowitz B, Hewlet I, Murthy KK, Cobb KE, Eichberg JW. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991;7:971-3.
18. 18 Vittecoq D, Chevret S, Morand-Joubert L, Heshmati F, Audat F, Bary M, Dusautoir T, Bismuth A, Viard JP, Barré-Sinoussi F, Bach JF, Lefrère JJ. Passive immunotherapy in AIDS. A double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995;92:1195-9.
19. 19 Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, Burke DS. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis 1994;169:48-54.
20. 20 Sawyer L, Wrin M, Crawford-Miksza L, Potts B, Wu Y, Weber P, Alfonso R, Hanson C. Neutralization sensitivity of human immunodeficiency virus type I is determined in part by the cell in which the virus is propagated. J Virol 1994;68:1342-9.
21. 21 Wrin T, Crawford L, Sawyer L, Weber P, Sheppard H, Hanson C. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:211-9.
22. 22 Barbas CF, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces. Gene III Site Proc Natl Acad Sci 1991;88:7978-82.
23. 23 Persson MAA, Caothien RH, Burton DR. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci USA 1991;88:2432-6.
24. 24 Burton DR, Barbas III FH, Persson MAA, Koenig S, Chanock RM, Lerner RA. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymthomatic seropositive individuals. Proc Natl Acad Sci USA 1991;88:10134-7.
25. 25 Pawels R, De Clercq E, Desmyter J, Balzarini J, Goubau P, Herdewijn P, Vanderhaeghe H, Van-Deputte M. Sensitive and rapid assay on MT-4 cells for the detection of antiviral compounds against the AIDS virus. J Virol Methods 1987;16:171-85.
26. 26 Berberian L, Goodglick L, Kipps TJ, Braun J. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 1993; 261:1588.
27. 27 Diaw L, Magnac C, Pritsch O, Buckle M, Alzari PM, Dighiero G. Structural and affinity studies of IgM polyreactive natural autoantibodies. J Immunol 1997;158:968-76.
28. 28 Goodglick L, Zevit N, Neshat MS, Braun J. Mapping the Ig super-antigen-binding site of HIV-1 gp120. J Immunol 1995;1995:5151-9.
29. 29 Tehernychev B, Cabilly S, Wilchek M. The epitopes for natural polireactive antibodies are rich in proline. Proc Natl Acad Sci USA 1997;94:6335-9.
30. 30 Limpanasithikul W, Ray S, Diamond B. Cross-reactive antibodies have both protective and pathogenic potential. J Immunol 1995;155: 967-73.
31. 31 Jukes TH., King JL.. Evolutionary nucleotide replacements in DUD. Nature 1979;281:605-6.